The US Food and Drug Administration (FDA) has granted orphan drug designation to Crossject's treatment for status epilepticus (epileptic seizure lasting longer than five minutes), ZENEO Midazolam.
This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData.
The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products.
Full-service contract manufacturer of biopharmaceutical proteins, Wacker Biotech, has obtained US Food and Drug Administration (FDA) approval to manufacture reteplase — the active ingredient in the drug Retavase.
The US Food and Drug Administration (FDA) has granted fast track designation to Infirst Healthcare’s haemoglobin spray, Granulox, for the treatment of diabetic foot ulcers (DFUs).
Drug discovery and development company, AiCuris, has been granted fast track designation by the US FDA for oral pritelivir — its lead candidate for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults.
An expensive cholesterol drug, evolocumab, which is prescribed on the NHS, is claimed to do nothing to prevent fatal heart attacks and strokes and a coalition of doctors have called for it to be withdrawn from use.
The FDA has approved the Raplixa fibrin sealant and the Raplixa spray device to provide adjunctive haemostasis for mild to moderate bleeding in adults in surgery.
